サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1679156

初代肝細胞市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年

Primary Hepatocytes Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 187 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
初代肝細胞市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年
出版日: 2025年03月11日
発行: Persistence Market Research
ページ情報: 英文 187 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、初代肝細胞の世界市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・促進要因・課題などの重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、世界の初代肝細胞市場の2025年から2032年までの予測成長軌道を概説する独占データと統計を掲載しています。

主な洞察

  • 初代肝細胞市場規模（2025年）：2億7,290万米ドル
  • 予測市場価値（2032年）：4億2,820万米ドル
  • 世界市場成長率（CAGR 2025～2032年）：6.6%

初代肝細胞市場- レポート範囲：

初代肝細胞は、製薬研究、毒性試験、薬剤開発に不可欠なツールとして機能する特殊な肝細胞です。これらの細胞は、創薬、肝毒性試験、肝疾患のin-vitroモデルなどに広く使用されています。初代肝細胞市場は、研究機関、製薬会社、医薬品開発業務受託機関（CRO）に対応しており、ヒト初代肝細胞、ラット肝細胞、不死化肝細胞など、さまざまな肝細胞製品を提供しています。市場成長の原動力は、個別化医療への需要の高まり、細胞培養技術の進歩、より正確な薬物検査モデルへのニーズの高まりです。

市場促進要因：

世界の初代肝細胞市場は、個別化医療に対する需要の高まり、創薬や毒性試験における信頼性の高い体外試験モデルに対するニーズの高まりなど、いくつかの主要な要因によって推進されています。肝細胞は、肝機能の評価、化合物の代謝、肝疾患の研究に極めて重要であり、医薬品の研究開発に広く採用されています。高度な肝細胞分離技術や改良された細胞培養システムの開発などの技術的進歩は、初代肝細胞の性能と有用性を高め、市場の拡大をさらに後押ししています。さらに、非動物実験法への注目の高まりや肝臓関連疾患の増加が、医学研究における初代肝細胞の採用拡大に寄与しています。

市場抑制要因：

有望な成長見通しにもかかわらず、初代肝細胞市場は、初代肝細胞分離培養システムの高コストに関する課題に直面しています。これらの技術には専門的な機器と熟練した人材が必要であり、小規模の研究所や予算が限られている機関では初代肝細胞を利用することが制限される可能性があります。さらに、ヒト肝組織の供給には限りがあり、肝細胞の調達に関連する倫理的な懸念が、市場成長の大きな障壁となる可能性があります。規制上のハードルや製薬研究における厳格なガイドライン遵守の必要性は、新規参入企業にとって市場参入をさらに複雑なものにしています。

市場機会：

初代肝細胞市場は、細胞培養技術の革新、肝疾患研究の進歩、代替薬物試験モデルに対する需要の増加により、大きな成長機会をもたらしています。肝硬変や肝炎などの慢性肝疾患の増加、個別化医療アプローチの採用拡大により、市場企業は肝細胞をベースとしたより効果的なソリューションを開発するための新たな手段を得ることができます。製薬企業、CRO、研究機関の戦略的パートナーシップは、研究開発への投資と並んで、新たな機会を活用し、市場でのリーダーシップを維持するために極めて重要です。

本レポートで扱う主な質問

  • 初代肝細胞市場の世界的成長を促進する主な要因は何か？
  • さまざまな研究環境において、どの肝細胞の種類と用途が初代肝細胞の需要を牽引しているのか？
  • 技術の進歩はどのように初代肝細胞市場の競合情勢を変えているのか？
  • 初代肝細胞市場に貢献している主要企業は誰であり、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の初代肝細胞市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
    • 世界のセクター別展望
    • 世界のGDP成長見通し
    • 世界のヘルスケア支出見通し
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

  • 規制状況
  • 製品採用分析
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の初代肝細胞市場の見通し：

  • 主なハイライト
    • 市場規模と前年比成長率
    • 絶対的収益機会
  • 市場規模分析と予測
    • 過去の市場規模分析、2019～2024年
    • 現在の市場規模の分析と予測、2025～2032年
  • 世界の初代肝細胞市場の見通し：製品
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、製品別、2019～2024年
    • 現在の市場規模分析と予測、製品別、2025～2032年
      • 凍結保存された浮遊肝細胞
      • 新鮮懸濁液肝細胞
      • 3D（スフェロイド）肝細胞
      • 増殖肝細胞（培養可能）
      • 未解析肝細胞
    • 市場の魅力分析：製品
  • 世界の初代肝細胞市場の見通し：種
    • イントロダクション/主な調査結果
    • 2019～2024年における種別市場規模の過去分析
    • 現在の市場規模分析と予測、種別、2025～2032年
      • 人間
      • ラット
      • マウス
      • 犬
      • 猿
      • 馬
      • その他
    • 市場の魅力分析：種
  • 世界の初代肝細胞市場の展望：アプリケーション/アッセイ
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、アプリケーション/アッセイ別、2019～2024年
    • 現在の市場規模の分析と予測、アプリケーション/アッセイ別、2025～2032年
      • 細胞生存率アッセイ
      • シトクロム酵素活性
      • 高濃度細胞毒性
      • トランスポーター阻害アッセイ
      • 体外固有クリアランス
      • リン脂質アッセイ
      • その他
    • 市場の魅力分析：アプリケーション/アッセイ
  • 世界の初代肝細胞市場の展望：エンドユーザー
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、エンドユーザー別、2019～2024年
    • 現在の市場規模の分析と予測、エンドユーザー別、2025～2032年
      • バイオ医薬品企業
      • 学術調査機関
      • 契約調査機関
    • 市場の魅力分析：エンドユーザー

第5章 世界の初代肝細胞市場の展望：地域

  • 主なハイライト
  • 2019～2024年地域別市場規模の歴史的分析
  • 現在の市場規模分析と予測、地域別、2025～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の初代肝細胞市場の見通し：

第7章 欧州の初代肝細胞市場の見通し：

第8章 東アジアの初代肝細胞市場の見通し：

第9章 南アジアおよびオセアニアの初代肝細胞市場の見通し：

第10章 ラテンアメリカの初代肝細胞市場の見通し：

第11章 中東およびアフリカの初代肝細胞市場の見通し：

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
    • 市場別の競合激化マップ
    • 競合ダッシュボード
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Lonza
    • Takara Bio Inc.
    • American Type Culture Collection（ATCC）
    • Corning Inc.
    • Cell Biologics, Inc.
    • Creative Bioarray
    • Axol Bioscience Ltd.
    • HiMedia Laboratories
    • NEXEL Co., Ltd.
    • AnaBios
    • Cytes Biotechnologies SL
    • ZenBio, Inc.（BioIVT）
    • iXCells Biotechnologies
    • ScienCell Research Laboratories, Inc.
    • Kerafast
    • Kosheeka
    • XenoTech
    • LifeNet Health LifeSciences
    • Cell Guidance Systems LLC
    • Applied Biological Materials Inc.（abm）
    • Discovery Life Sciences
    • Innoprot
    • Novabiosis

第13章 付録

  • 調査手法
  • 調査の前提
  • 頭字語と略語
目次
Product Code: PMRREP32880

Persistence Market Research has recently released a comprehensive report on the worldwide market for primary hepatocytes. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global primary hepatocytes market from 2025 to 2032.

Key Insights:

  • Primary Hepatocytes Market Size (2025E): US$ 272.9 Mn
  • Projected Market Value (2032F): US$ 428.2 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.6%

Primary Hepatocytes Market - Report Scope:

Primary hepatocytes are specialized liver cells that serve as essential tools for pharmaceutical research, toxicity testing, and drug development. These cells are widely used in drug discovery, hepatotoxicity testing, and in-vitro models for liver diseases. The primary hepatocytes market caters to research institutions, pharmaceutical companies, and contract research organizations (CROs), offering a variety of hepatocyte products, including human primary hepatocytes, rat hepatocytes, and immortalized hepatocytes. Market growth is driven by increasing demand for personalized medicine, advancements in cell culture technology, and the rising need for more accurate drug testing models.

Market Growth Drivers:

The global primary hepatocytes market is propelled by several key factors, including the growing demand for personalized medicine and the rising need for reliable in-vitro testing models in drug discovery and toxicity testing. Hepatocytes are crucial in assessing liver function, metabolizing compounds, and studying liver diseases, leading to their widespread adoption in pharmaceutical R&D. Technological advancements, such as the development of advanced hepatocyte isolation techniques and improved cell culture systems, have enhanced the performance and utility of primary hepatocytes, further boosting market expansion. Moreover, the growing focus on non-animal testing methods and the increasing number of liver-related diseases contribute to the rising adoption of primary hepatocytes in medical research.

Market Restraints:

Despite promising growth prospects, the primary hepatocytes market faces challenges related to the high cost of primary hepatocyte isolation and culture systems. These techniques require specialized equipment and skilled personnel, which can limit the accessibility of primary hepatocytes to smaller laboratories or institutions with limited budgets. Additionally, the limited supply of human liver tissue and ethical concerns associated with sourcing hepatocytes can pose significant barriers to market growth. Regulatory hurdles and the need for compliance with stringent guidelines in pharmaceutical research further complicate market entry for new players.

Market Opportunities:

The primary hepatocytes market presents significant growth opportunities driven by innovations in cell culture technology, advancements in liver disease research, and increasing demand for alternative drug testing models. The rise in chronic liver diseases such as cirrhosis and hepatitis, along with the growing adoption of personalized medicine approaches, provides new avenues for market players to develop more effective hepatocyte-based solutions. Strategic partnerships between pharmaceutical companies, CROs, and research institutions, alongside investments in R&D, are crucial to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the primary hepatocytes market globally?
  • Which hepatocyte types and applications are driving the demand for primary hepatocytes across different research settings?
  • How are technological advancements reshaping the competitive landscape of the primary hepatocytes market?
  • Who are the key players contributing to the primary hepatocytes market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global primary hepatocytes market?

Competitive Intelligence and Business Strategy:

Leading players in the global primary hepatocytes market, including Thermo Fisher Scientific, Lonza Group, and Merck KGaA, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced hepatocyte culture systems, liver-on-a-chip models, and improved hepatocyte isolation techniques, catering to diverse research needs. Collaborations with pharmaceutical companies, biotechnology firms, and academic research institutions facilitate market access and promote the development of more effective hepatocyte-based solutions. Moreover, emphasis on clinical research, drug development, and regulatory compliance fosters market growth and enhances product offerings in the evolving hepatocyte market.

Key Companies Profiled:

  • Thermo Fisher Scientific
  • Lonza Group
  • Merck KGaA
  • Sigma-Aldrich (now part of Merck)
  • BioIVT
  • CellzDirect (a part of Thermo Fisher)
  • In Vitro Technologies
  • Primorigen Biosciences
  • PharmaCyte Biotech
  • Wuxi AppTec

Global Primary Hepatocytes Market Segmentation

By Product

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse

By Application/Assay

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay

By End User

  • Biopharmaceutical companies
  • Academic and Research institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Primary Hepatocytes Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Primary Hepatocytes Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Cryopreserved Suspension Hepatocytes
      • 4.3.3.2. Fresh Suspension Hepatocytes
      • 4.3.3.3. 3D (Spheroid) Hepatocytes
      • 4.3.3.4. Expanded Hepatocytes (Plateable)
      • 4.3.3.5. Non-characterized Hepatocytes
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Primary Hepatocytes Market Outlook: Species
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Species, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
      • 4.4.3.1. Human
      • 4.4.3.2. Rat
      • 4.4.3.3. Mouse
      • 4.4.3.4. Dog
      • 4.4.3.5. Monkey
      • 4.4.3.6. Horse
      • 4.4.3.7. Others
    • 4.4.4. Market Attractiveness Analysis: Species
  • 4.5. Global Primary Hepatocytes Market Outlook: Application/Assay
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Application/Assay, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
      • 4.5.3.1. Cell Viability Assay
      • 4.5.3.2. Cytochrome Enzyme Activity
      • 4.5.3.3. High Content Cytotoxicity
      • 4.5.3.4. Transporter Inhibition Assay
      • 4.5.3.5. In Vitro Intrinsic Clearance
      • 4.5.3.6. Phospholipids Assay
      • 4.5.3.7. Others
    • 4.5.4. Market Attractiveness Analysis: Application/Assay
  • 4.6. Global Primary Hepatocytes Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Biopharmaceutical companies
      • 4.6.3.2. Academic and Research institutes
      • 4.6.3.3. Contract Research Organizations
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Primary Hepatocytes Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Primary Hepatocytes Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Species
    • 6.2.4. By Application/Assay
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Cryopreserved Suspension Hepatocytes
    • 6.4.2. Fresh Suspension Hepatocytes
    • 6.4.3. 3D (Spheroid) Hepatocytes
    • 6.4.4. Expanded Hepatocytes (Plateable)
    • 6.4.5. Non-characterized Hepatocytes
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 6.5.1. Human
    • 6.5.2. Rat
    • 6.5.3. Mouse
    • 6.5.4. Dog
    • 6.5.5. Monkey
    • 6.5.6. Horse
    • 6.5.7. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 6.6.1. Cell Viability Assay
    • 6.6.2. Cytochrome Enzyme Activity
    • 6.6.3. High Content Cytotoxicity
    • 6.6.4. Transporter Inhibition Assay
    • 6.6.5. In Vitro Intrinsic Clearance
    • 6.6.6. Phospholipids Assay
    • 6.6.7. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Biopharmaceutical companies
    • 6.7.2. Academic and Research institutes
    • 6.7.3. Contract Research Organizations
  • 6.8. Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Species
    • 7.2.4. By Application/Assay
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Cryopreserved Suspension Hepatocytes
    • 7.4.2. Fresh Suspension Hepatocytes
    • 7.4.3. 3D (Spheroid) Hepatocytes
    • 7.4.4. Expanded Hepatocytes (Plateable)
    • 7.4.5. Non-characterized Hepatocytes
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 7.5.1. Human
    • 7.5.2. Rat
    • 7.5.3. Mouse
    • 7.5.4. Dog
    • 7.5.5. Monkey
    • 7.5.6. Horse
    • 7.5.7. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 7.6.1. Cell Viability Assay
    • 7.6.2. Cytochrome Enzyme Activity
    • 7.6.3. High Content Cytotoxicity
    • 7.6.4. Transporter Inhibition Assay
    • 7.6.5. In Vitro Intrinsic Clearance
    • 7.6.6. Phospholipids Assay
    • 7.6.7. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Biopharmaceutical companies
    • 7.7.2. Academic and Research institutes
    • 7.7.3. Contract Research Organizations
  • 7.8. Market Attractiveness Analysis

8. East Asia Primary Hepatocytes Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Species
    • 8.2.4. By Application/Assay
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Cryopreserved Suspension Hepatocytes
    • 8.4.2. Fresh Suspension Hepatocytes
    • 8.4.3. 3D (Spheroid) Hepatocytes
    • 8.4.4. Expanded Hepatocytes (Plateable)
    • 8.4.5. Non-characterized Hepatocytes
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 8.5.1. Human
    • 8.5.2. Rat
    • 8.5.3. Mouse
    • 8.5.4. Dog
    • 8.5.5. Monkey
    • 8.5.6. Horse
    • 8.5.7. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 8.6.1. Cell Viability Assay
    • 8.6.2. Cytochrome Enzyme Activity
    • 8.6.3. High Content Cytotoxicity
    • 8.6.4. Transporter Inhibition Assay
    • 8.6.5. In Vitro Intrinsic Clearance
    • 8.6.6. Phospholipids Assay
    • 8.6.7. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Biopharmaceutical companies
    • 8.7.2. Academic and Research institutes
    • 8.7.3. Contract Research Organizations
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Primary Hepatocytes Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Species
    • 9.2.4. By Application/Assay
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Cryopreserved Suspension Hepatocytes
    • 9.4.2. Fresh Suspension Hepatocytes
    • 9.4.3. 3D (Spheroid) Hepatocytes
    • 9.4.4. Expanded Hepatocytes (Plateable)
    • 9.4.5. Non-characterized Hepatocytes
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 9.5.1. Human
    • 9.5.2. Rat
    • 9.5.3. Mouse
    • 9.5.4. Dog
    • 9.5.5. Monkey
    • 9.5.6. Horse
    • 9.5.7. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 9.6.1. Cell Viability Assay
    • 9.6.2. Cytochrome Enzyme Activity
    • 9.6.3. High Content Cytotoxicity
    • 9.6.4. Transporter Inhibition Assay
    • 9.6.5. In Vitro Intrinsic Clearance
    • 9.6.6. Phospholipids Assay
    • 9.6.7. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Biopharmaceutical companies
    • 9.7.2. Academic and Research institutes
    • 9.7.3. Contract Research Organizations
  • 9.8. Market Attractiveness Analysis

10. Latin America Primary Hepatocytes Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Species
    • 10.2.4. By Application/Assay
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Cryopreserved Suspension Hepatocytes
    • 10.4.2. Fresh Suspension Hepatocytes
    • 10.4.3. 3D (Spheroid) Hepatocytes
    • 10.4.4. Expanded Hepatocytes (Plateable)
    • 10.4.5. Non-characterized Hepatocytes
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 10.5.1. Human
    • 10.5.2. Rat
    • 10.5.3. Mouse
    • 10.5.4. Dog
    • 10.5.5. Monkey
    • 10.5.6. Horse
    • 10.5.7. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 10.6.1. Cell Viability Assay
    • 10.6.2. Cytochrome Enzyme Activity
    • 10.6.3. High Content Cytotoxicity
    • 10.6.4. Transporter Inhibition Assay
    • 10.6.5. In Vitro Intrinsic Clearance
    • 10.6.6. Phospholipids Assay
    • 10.6.7. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Biopharmaceutical companies
    • 10.7.2. Academic and Research institutes
    • 10.7.3. Contract Research Organizations
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Primary Hepatocytes Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Species
    • 11.2.4. By Application/Assay
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Cryopreserved Suspension Hepatocytes
    • 11.4.2. Fresh Suspension Hepatocytes
    • 11.4.3. 3D (Spheroid) Hepatocytes
    • 11.4.4. Expanded Hepatocytes (Plateable)
    • 11.4.5. Non-characterized Hepatocytes
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 11.5.1. Human
    • 11.5.2. Rat
    • 11.5.3. Mouse
    • 11.5.4. Dog
    • 11.5.5. Monkey
    • 11.5.6. Horse
    • 11.5.7. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 11.6.1. Cell Viability Assay
    • 11.6.2. Cytochrome Enzyme Activity
    • 11.6.3. High Content Cytotoxicity
    • 11.6.4. Transporter Inhibition Assay
    • 11.6.5. In Vitro Intrinsic Clearance
    • 11.6.6. Phospholipids Assay
    • 11.6.7. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Biopharmaceutical companies
    • 11.7.2. Academic and Research institutes
    • 11.7.3. Contract Research Organizations
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Thermo Fisher Scientific Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Merck KGaA
    • 12.3.3. Lonza
    • 12.3.4. Takara Bio Inc.
    • 12.3.5. American Type Culture Collection (ATCC)
    • 12.3.6. Corning Inc.
    • 12.3.7. Cell Biologics, Inc.
    • 12.3.8. Creative Bioarray
    • 12.3.9. Axol Bioscience Ltd.
    • 12.3.10. HiMedia Laboratories
    • 12.3.11. NEXEL Co., Ltd.
    • 12.3.12. AnaBios
    • 12.3.13. Cytes Biotechnologies S.L.
    • 12.3.14. ZenBio, Inc. (BioIVT)
    • 12.3.15. iXCells Biotechnologies
    • 12.3.16. ScienCell Research Laboratories, Inc.
    • 12.3.17. Kerafast
    • 12.3.18. Kosheeka
    • 12.3.19. XenoTech
    • 12.3.20. LifeNet Health LifeSciences
    • 12.3.21. Cell Guidance Systems LLC
    • 12.3.22. Applied Biological Materials Inc. (abm)
    • 12.3.23. Discovery Life Sciences
    • 12.3.24. Innoprot
    • 12.3.25. Novabiosis

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations